Wanbury Ltd.

₹187.93

24.6 (15.1%)

WANBURY Share Price

Pharmaceuticals & Biotechnology

As on January 28, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 646 Cr

P/E Ratio20.17

Dividend YieldN/A

Trendline Performance

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	178.97	Bullish
10-DMA	195.38	Bearish
20-DMA	210.34	Bearish
50-DMA	226.68	Bearish
100-DMA	239.69	Bearish
200-DMA	255.76	Bearish

Historical Performance

1 Year

-14.4%

3 Years

331.5%

5 Years

213.2%

10 Years

208.1%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	5,995	5,777	4,996	5,112	3,925
Total Expenditure	5,318	5,056	4,766	4,795	3,768
Other Income	121	9	10	51	48
Operating Profit	798	730	241	368	204
Interest	370	292	214	206	231
Depreciation	133	130	124	114	98
Profit Before Tax	296	563	-103	811	-124
Consolidated Net Profit	305	560	-104	815	-126
Adjusted EPS	9	17	-3	25	-5

Compounded Sales Growth

10 Years:7.2

5 Years:10.3

3 Years:3.2

TTM:0.7

Compounded Profit Growth

10 Years:8.2

5 Years:-13.9

3 Years:-17.8

TTM:-11.4

Stock Price CAGR

10 Years:12.2

5 Years:26

3 Years:62.8

TTM:-13.5

Return on Equity

10 Years:-3.6

5 Years:-5

3 Years:-3.2

last year:9.3

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	328	327	327	327	250
Total Reserves	186	-116	-672	-570	-1,816
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	1,730	990	108	106	844
Other Current Liabilities	294	316	1,539	1,624	2,006
Short Term Borrowings	42	143	132	132	164
Total Liabilities	4,069	3,376	2,980	3,469	2,835
Capital Work in Progress	54	30	16	23	110
Long Term Loans & Advances	59	57	50	38	34
Currents Investments	1	---	---	---	---
Short Term Loans and Advances	249	213	229	280	34
Total Current Assets	1,934	1,586	1,218	1,712	975
Total Assets	4,069	3,376	2,980	3,469	2,835
Adjusted Book Value	16	6	-11	-8	-63

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 20.17, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a strong 3-year price CAGR of 63.8%, indicating sustained price appreciation.
The stock carries a high beta of 1.4, implying higher volatility and elevated risk.
In the last financial year, the company reported an EBITDA of ₹798 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹5995 million, suggesting a mid-sized operation.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 864841.2

No. of Shares: 4602 (Approx)

Performance:-13.5%

P/L: ₹-135158.8

NIFTY Performance: 9.4%

1 day Top Gainers